

216 Life Sciences Center Columbia, Missouri 65211-7310

PHONE: (573) 882-0428

E-MAIL: mugenomicscore@missouri.edu

WEB: dnacore.missouri.edu

Biosafety Questionnaire (Human and Animal Samples)

Researchers bring samples derived from a variety of sources for analysis, and these samples can potentially harbor pathogens capable of transmitting disease. Therefore, please fill out this questionnaire and include as many details as possible. The principal investigator should sign and submit the completed form to the GTC **before** the planned experiment. Once the GTCdirector approves the form the experiment will be scheduled.

Project Title:		
Principal Investigator:	E-mail:	
Project start and end dates: Start:	End:	
Does this project have a current Institu	tional Biosafety Committee (IBC) approval?	
Yes. Attach a copy of IBC approval Lette	er or IBC protocol number. IBC protocol#	
No. If no, the samples cannot be run until Environmental Health & Safety Office at	the IBC has approved the study. Questions? Contact the (573) 882-7018	
Exempt. (No known infectious agen	nts or exempt from IBC approval)	
Briefly summarize the project:		
List the origin (tissue) and species of th Human Mouse Rat Zeb	e sample (e.g., mouse spleen cells). orafish Drosophila Dother	
Primary cells		
List species and tissue:		
Established cell lines		
Name of cell line, species, and tissue		
Has the cell line been transformed by or ca	arry any known viral pathogens?	
If ves. provide details:		



216 Life Sciences Center Columbia, Missouri 65211-7310

PHONE: (573) 882-0428

E-MAIL: mugenomics core@missouri.edu WEB: dnacore.missouri.edu

Do the samples contain any known infectious agents or other known human pathogens?
☐ Yes ☐ No
If yes, list infectious agents or known human pathogens:
Note: The infectious agents/known pathogens and containment method must be listed on your IBC approval letter.
Has the infectious agent been inactivated or rendered non-infectious? Yes No Not applicable
If yes, describe method of inactivation. Provide proof of inactivation, if applicable.
Have the cells been transformed or genetically engineered using a viral system (e.g., EBV) or recombinant DNA? Yes No
If yes, has a gene therapy virus been used?
Yes No
Plasmid or viral vector: (e.g., LentiMax)
Details about insert:
Is the insert an oncogene: Yes No If yes, provide details of insert:
If virus, is it replication incompetent?
Entering your name indicates you have read above questions carefully and certify the information provided to be correct
Name Date (mm/dd/year)
Title





PHONE: (573) 882-0428

E-MAIL: mugenomics core@missouri.edu WEB: dnacore.missouri.edu

FOR DNACF USE ONLY		
COMMENTS		
BIOSAFETY LEVEL:		
APPROVED: YesNoDATE:		
APPROVED BY:		